Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions
AEG Osman, MW Deininger - Blood reviews, 2021 - Elsevier
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by a reciprocal
translocation [t (9; 22)(q34; q11. 2)] that leads to the fusion of ABL1 gene sequences (9q34) …
translocation [t (9; 22)(q34; q11. 2)] that leads to the fusion of ABL1 gene sequences (9q34) …
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
JL Steegmann, M Baccarani, M Breccia, LF Casado… - Leukemia, 2016 - nature.com
Most reports on chronic myeloid leukaemia (CML) treatment with tyrosine kinase inhibitors
(TKIs) focus on efficacy, particularly on molecular response and outcome. In contrast …
(TKIs) focus on efficacy, particularly on molecular response and outcome. In contrast …
Chronic myeloid leukemia, version 2.2021, NCCN clinical practice guidelines in oncology
MW Deininger, NP Shah, JK Altman, E Berman… - Journal of the National …, 2020 - jnccn.org
Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
(Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] …
(Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] …
Chronic myeloid leukemia, version 1.2019, NCCN clinical practice guidelines in oncology
JP Radich, M Deininger, CN Abboud, JK Altman… - Journal of the National …, 2018 - jnccn.org
Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
(Ph), resulting from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] that …
(Ph), resulting from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] that …
Incidence, diagnosis, and management of QT prolongation induced by cancer therapies: a systematic review
A Porta‐Sánchez, C Gilbert, D Spears… - Journal of the …, 2017 - Am Heart Assoc
Background The cardiovascular complications of cancer therapeutics are the focus of the
burgeoning field of cardio‐oncology. A common challenge in this field is the impact of …
burgeoning field of cardio‐oncology. A common challenge in this field is the impact of …
Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV
L Kalmanti, S Saußele, M Lauseker, MC Müller… - Leukemia, 2015 - nature.com
Tyrosine kinase inhibitors (TKI) have changed the natural course of chronic myeloid
leukemia (CML). With the advent of second-generation TKI safety and efficacy issues have …
leukemia (CML). With the advent of second-generation TKI safety and efficacy issues have …
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML …
R Hehlmann, M Lauseker, S Saußele, M Pfirrmann… - Leukemia, 2017 - nature.com
Chronic myeloid leukemia (CML)-study IV was designed to explore whether treatment with
imatinib (IM) at 400 mg/day (n= 400) could be optimized by doubling the dose (n= 420) …
imatinib (IM) at 400 mg/day (n= 400) could be optimized by doubling the dose (n= 420) …
Chronic myeloid leukemia, version 2.2024, nccn clinical practice guidelines in oncology
NP Shah, R Bhatia, JK Altman, M Amaya… - Journal of the National …, 2024 - jnccn.org
Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
resulting from a reciprocal translocation between chromosomes 9 and 22 [t9; 22] that gives …
resulting from a reciprocal translocation between chromosomes 9 and 22 [t9; 22] that gives …
[HTML][HTML] Chronic myeloid leukemia: reminiscences and dreams
With the deaths of Janet Rowley and John Goldman in December 2013, the world lost two
pioneers in the field of chronic myeloid leukemia. In 1973, Janet Rowley, unraveled the …
pioneers in the field of chronic myeloid leukemia. In 1973, Janet Rowley, unraveled the …
Long‐term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib
JE Cortes, HJ Khoury, HM Kantarjian… - American journal of …, 2016 - Wiley Online Library
Bosutinib is an Src/Abl tyrosine kinase inhibitor (TKI) indicated for adults with Ph+ chronic
myeloid leukemia (CML) resistant/intolerant to prior TKIs. This long‐term update of an …
myeloid leukemia (CML) resistant/intolerant to prior TKIs. This long‐term update of an …